Cantor Fitzgerald analyst Steve Seedhouse initiated coverage of Harrow (HROW) with an Overweight rating and $76 price target The firm cites a path to strong growth and profitability, and believes Harrow is on a path to become the leading diversified U.S. ophthalmology company, the analyst tells investors in a research note. Cantor says Harrow has a “very good” setup for Q2, and guidance for 2025 is potentially conservative.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW: